psychedelics biotech Awakn Life Sciences corp AWKNF announced the continuation of its Nordic expansion plans with a new 5-year lease to open a clinic in central Trondheim.

Anthony Tennyson, CEO of Awakn, said this is “real growth momentum” for the company in Norway.

“Within a week to share news our move to a new, larger building in Oslo and a whole new clinic in Trondheim is very exciting. For so many people who are suffering and desperately need a new, more effective treatment, this will be great news for them,” said Tennyson.

The company’s Nordic expansion will be overseen by its Regional Director for the Nordics, Dr. Lowan Stewart, a well-respected figure in this medical community and the one responsible for introducing ketamine therapy into Norway’s public health system.

The new Trondheim facility will be led by prominent Norwegian psychiatrist Dr. Ingrid Casterberg and will consist of a three treatment room clinic totaling 1,400 square feet, expected to be complete sometime in March or April 2023.

Awakn’s leading-edge ketamine treatment protocols are applied at the company’s clinics, taking into account each client’s mental health status Awakn’s CMO Ben Sessa said Benzinga earlier this year.

The Alcohol Use Disorder (AUD) protocol in particular has delivered such robust positive results that the company has entered into a partnership several ketamine centers throughout North America for license agreements to implement this therapy in companies not owned by Awakn.

Photo courtesy of michaeljung on Shutterstock and Wikimedia Commons.